Recurrent Pterygium Clinical Trial
Official title:
Triple Subconjunctival Bevacizumab Injection for Early Recurrent Pterygium. One Year Follow-up
Verified date | March 2018 |
Source | Instituto de Oftalmología Fundación Conde de Valenciana |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Blockade of vascular endothelial growth factor (VEGF) with bevacizumab has been used to treat abnormal vascular conditions of the anterior segment of the eye. In pterygium, anti-VEGF agents have been recently proposed as primary treatments, such as perioperative adjuvants, as well as treatments for pterygia recurrences after surgery. The aim of the present study was to prospectively evaluate the effect of three subconjunctival bevacizumab injections in patients with an early pterygium recurrence. Materials and Methods: The current study was a non-randomized single central trial. The method of ensuring allocation concealment was sequentially numbered. Patients with an early pterygium recurrence were selected and invited to participate in the study. Recurrence was defined as the presence of corneal vessels with concomitant conjunctival hyperemia within the first trimester after primary pterygium removal, and only patients with primary pterygium recurrence were included. Patient related factors such as pregnancy, women seeking to become pregnant, and lactating women were excluded from the study. All patients received three subconjunctival bevacizumab (2.5 mg/0.05 ml) injections (basal, 2 and 4 weeks) in the recurrence area of the pterygium, and were photographed at the third, sixth and twelfth months after the last bevacizumab injection. Photographic analyses were performed taking into account two pterygium areas: the first measure included only the vessel area in the corneal surface, while the second measure included, both, conjunctival and corneal vessel area (corneal-conjunctival area of hyperemia). Neovascularization area of each pterygium was determined using digital slit lam pictures, which were analyzed using Photoshop CS4, in order to get pixels measurements of the lesion.
Status | Completed |
Enrollment | 38 |
Est. completion date | August 2013 |
Est. primary completion date | August 2013 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Patients with an early pterygium recurrence were selected and invited to participate in the study. Recurrence was defined as the presence of corneal vessels with concomitant conjunctival hyperemia within the first trimester after primary pterygium removal, and only patients with primary pterygium recurrence were included Exclusion Criteria: - Patient related factors such as pregnancy, women seeking to become pregnant, and lactating women. Patients with diabetes Mellitus and colagenopathies. |
Country | Name | City | State |
---|---|---|---|
Mexico | Institute of Ophthalmology, Conde de Valenciana Foundation | Mexico, City | Mexico City |
Lead Sponsor | Collaborator |
---|---|
Instituto de Oftalmología Fundación Conde de Valenciana | National Council of Science and Technology, Mexico |
Mexico,
Nava-Castaneda A, Tovilla-Canales JL, Rodriguez L, Tovilla Y Pomar JL, Jones CE. Effects of lacrimal occlusion with collagen and silicone plugs on patients with conjunctivitis associated with dry eye. Cornea. 2003 Jan;22(1):10-4. — View Citation
Nava-Castañeda A, Ulloa-Orozco I, Garnica-Hayashi L, Hernandez-Orgaz J, Jimenez-Martinez MC, Garfias Y. Triple subconjunctival bevacizumab injection for early corneal recurrent pterygium: one-year follow-up. J Ocul Pharmacol Ther. 2015 Mar;31(2):106-13. doi: 10.1089/jop.2014.0060. Epub 2014 Nov 4. — View Citation
Welch MN, Reilly CD, Kalwerisky K, Johnson A, Waller SG. Pterygia measurements are more accurate with anterior segment optical coherence tomography - a pilot study. Nepal J Ophthalmol. 2011 Jan-Jun;3(1):9-12. doi: 10.3126/nepjoph.v3i1.4271. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Symptoms evaluation | The frequency of symptoms (redness, watery eyes, itching, burning, foreign body sensation, and fluctuating vision) were evaluated according to Nava-CastaƱeda et al Questionnaire (2003). Symptoms were graded as follows: 0, never; 1, rarely (once a week); 2, occasionally (several times a week); 3, frequently (once a day); 4, usually (several times a day); and 5, continually (every hour of the day). In addition, the severity of these signs/sympots were scored at each visit on a scale of 0 to 3, with 0 representing the absence of the symptom, 1 mild, 2 moderate, and 3 severe. A total symptoms score, which is a measure of the overall severity of the patients,s conjunctival condition, was calculated by multiplying (for each individual symptom/condition) the numerical values corresponding to frequency and severity, and then adding the products for all symptoms. | One year | |
Primary | Pterygium recurrence | Evidence of vessel growth on both, corneal and conjunctival area after bevacizumab treatment | One year | |
Secondary | Pterygia measurements | Measurements were performed according to Welch et al. modified technique as following: the distance in millimeters from the limbus to the apex of the lesion on the cornea (horizontal length) was performed using the slit-lamp beam (BQ 900, Haag-Streit, Koeniz, Switzerland). A standard magnification of 16 was used and the variable aperture was focused from the limbus to the apex. | One year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02486484 -
Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF Injection
|
Phase 2 | |
Completed |
NCT05362253 -
Micro-Conjunctival Autografting Combined With Amniotic Membrane Transplantation Treating Recurrent Pterygium Trial
|
N/A | |
Active, not recruiting |
NCT02530801 -
Strategies for Management of Recurrent Pterygium
|
Phase 4 | |
Recruiting |
NCT04463901 -
Conjunctival Autograft or Limbal Conjunctival Autograft for Recurrent Pterygium Using Mitomycin C
|
N/A | |
Completed |
NCT01744756 -
Subconjunctival Bevacizumab and Recurrent Pterygium
|
Phase 2/Phase 3 | |
Completed |
NCT02059837 -
Clinical Analysis of Recurrence Patterns Following Conjunctival Autografts for Pterygium Surgery
|
N/A | |
Completed |
NCT01319721 -
Recurrent Pterygium Surgery Using Mitomycin C With Limbal Conjunctival or Amniotic Membrane
|
N/A |